Lantern Pharma Inc. (LTRN)
LTRN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | LTRN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001763950 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | TX |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "For this reason, there is substantial doubt about the Company's ability to continue as a going concern in the absence of obtaining substantial additional funding." | 10-Q 2026-08-14 |
| Cash and burn | $6.7M cash; operating cash flow -$3.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | 12,784,146 (2026-08-10); 10,799,417 a year earlier; 10,869,040 three years earlier. | Cover page 2026-08-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-09-30 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-10-01 |
| Auditor | EisnerAmper LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $100K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$7.1M | -$2.9M | $6.7M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$3.3M | -$3.8M | $4.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | Not filed | -$4.1M | -$2.8M | $4.4M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$4.2M | -$4.6M | $8.4M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$4.3M | -$3.9M | $6.1M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$4.5M | -$4.4M | $6.4M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$5.9M | -$4.0M | $7.5M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$4.5M | -$5.6M | $8.1M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-30 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report | 8-K | 2026-10-01 |
| Latest proxy | DEF 14A | 2026-10-19 |
Source: SEC EDGAR submissions feed, 263 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -23.8% |
| 1 month | -39.1% |
| 3 months | -83.5% |
| Year to date | -85.7% |
| 1 year | -87.5% |
| From 52-week high | -89.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| APRE | Aprea Therapeutics Inc. | $0.4063 | -2.38% | $5.8M |
| BLRX | BioLineRx Ltd. | $1.15 | -12.61% | $5.7M |
| ALZN | Alzamend Neuro Inc. | $1.18 | -4.84% | $5.7M |
| ACXP | Acurx Pharmaceuticals Inc. | $0.9350 | -2.60% | $5.7M |
| FBLG | FibroBiologics Inc. | $0.9034 | -2.00% | $6.1M |
| TOVX | Theriva Biologics Inc. | $0.1400 | -2.85% | $6.4M |
| ENVB | Enveric Biosciences Inc. | $1.44 | -4.95% | $6.4M |
| ADXN | Addex Therapeutics Ltd | $3.83 | -5.67% | $6.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier